Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Nilotinib Vs. Dasatinib in Achieving MR 4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-134168

Published: 2020

Journal Articles

Interleukin 1 Beta As a Promising Therapeutic Target in ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yuko Tanaka, Kazuma Ohyashiki, MD PhD

Blood (2018) 132 (Supplement 1): 4249.

https://doi.org/10.1182/blood-2018-99-114030

Published: 2018

Journal Articles

Targeting Insulin-like Growth Factor in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant Cells

Yuko Tanaka, Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yoshikazu Ito, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2018) 132 (Supplement 1): 5155.

https://doi.org/10.1182/blood-2018-99-114750

Published: 2018

Journal Articles

Aurora A Kinase As a Promising Therapeutic Target in Philadelphia Chromosome Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 3828.

https://doi.org/10.1182/blood.V130.Suppl_1.3828.3828

Published: 2017

Journal Articles

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Aaron T. Gerds, MDMS, Tetsuzo Tauchi, MD, Ellen K. Ritchie, MD, Michael W. Deininger, MD PhD, Catriona HM Jamieson, MD PhD, Ruben Mesa, MD FACP, Mark Lawrence Heaney, MD PhD, Norio Komatsu, MD PhD, Hironobu Minami, MD PhD, M. Naveed Shaik, PhD, Xiaoxi Zhang, PhD, Christine DiRienzo, PhD, Mirjana Zeremski, MD, Geoffrey Chan, MD, Moshe Talpaz, MD

Blood (2017) 130 (Supplement 1): 258.

https://doi.org/10.1182/blood.V130.Suppl_1.258.258

Published: 2017

Journal Articles

ABL001 with Catalytic-Site Inhibitors Limit the CML Immature Cell Population: Re-Differentiation of CML-iPSCs Study

Tetsuzo Tauchi, MD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 1582.

https://doi.org/10.1182/blood.V130.Suppl_1.1582.1582

Published: 2017

Journal Articles

Peroxisome Proliferator-Activated Receptors: Targets for the Treatment of Philadelphia Chromosome-Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 5241.

https://doi.org/10.1182/blood.V130.Suppl_1.5241.5241

Published: 2017

Journal Articles

Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC)

Tetsuzo Tauchi, MD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 1249.

https://doi.org/10.1182/blood.V130.Suppl_1.1249.1249

Published: 2017

Journal Articles

Anti-Leukemic Effects of Venetoclax on Philadelphia Chromosome Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2016) 128 (22): 5428.

https://doi.org/10.1182/blood.V128.22.5428.5428

Published: 2016

Journal Articles

Anti-Leukemic Activity of Phosphoinositide 3-Kinase Inhibitor, Copanlisib in ABL Tyrosine Kinase Resistant Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yuko Tanaka, MDPhD, Seiichiro Katagiri, MD PhD, Kazuma Ohyashiki

Blood (2014) 124 (21): 3127.

https://doi.org/10.1182/blood.V124.21.3127.3127

Published: 2014

Journal Articles

Antitumor Activity of Phosphoinositide 3-Kinases Inhibitor, Copanlisib in Multiple Myeloma Cells

Yuko Tanaka, MDPhD, Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yoshikazu Ito, MD PhD, Kazuma Ohyashiki

Blood (2014) 124 (21): 5755.

https://doi.org/10.1182/blood.V124.21.5755.5755

Published: 2014

Journal Articles

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Seiichiro Katagiri, MD PhD, Tetsuzo Tauchi, MD PhD, Yuu Saito, MD, Tamiko Sugro, MD, Michiyo Asano, MD, Seiichiro Yoshizawa, MD PhD, Juri Sakuta, MD PhD, Daigo Akahane, MD PhD, Yuko Tanaka, MD PhD, Nahoko Furuya, MD PhD, Keiko Ando, MD PhD, Hiroaki Fujimoto, MD, Seiichi Okabe, MD PhD, Moritaka Gotoh, MD PhD, Yoshikazu Ito, MD PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2014) 124 (21): 1797.

https://doi.org/10.1182/blood.V124.21.1797.1797

Published: 2014

Journal Articles

Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Tetsuzo Tauchi, MD PhD, Seiichiro Katagiri, MD, Seiichi Okabe, MD PhD, Yuko Tanaka, MDPhD, Kazuma Ohyashiki, MD, PhD

Blood (2014) 124 (21): 905.

https://doi.org/10.1182/blood.V124.21.905.905

Published: 2014

Journal Articles

Efficacy Of The Polo-Like Kinase Inhibitor, Rigosertib Alone Or In Combination With ABL Tyrosine Kinase Inhibitor Against BCR-ABL-Positive Leukemia Cells

Seiichi Okabe, MD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD, Toshihiko Kitahara, MD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 3985.

https://doi.org/10.1182/blood.V122.21.3985.3985

Published: 2013

Journal Articles

High Frequencies Of Switching To 2 nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants

Seiichiro Katagiri, MD, Tetsuzo Tauchi, MD, Tomohiro Umezu, PhD, Kazuhiro Ohtsuki, PhD, Kenichi Tadokoro, Yoshinori Yamamoto, Junko H Ohyashiki, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 4021.

https://doi.org/10.1182/blood.V122.21.4021.4021

Published: 2013

Journal Articles

Therapeutic Potential Of Targeting Sphingosine-1-Phosuphate and Sphingosine Kinases In Multiple Myeloma

Yuko Tanaka, MD, Seiichi Okabe, MD, Tetsuzo Tauchi, MD, Yoshikazu Ito, MD, PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 1894.

https://doi.org/10.1182/blood.V122.21.1894.1894

Published: 2013

Journal Articles

Activity Of Omacetaxine Mepesuccinate Against Ponatinib Resistant Philadelphia Chromosome Positive Leukemia Cells

Seiichi Okabe, MD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD, Seiichiro Katagiri, MD, Toshihiko Kitahara, MD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 3840.

https://doi.org/10.1182/blood.V122.21.3840.3840

Published: 2013

Journal Articles

A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF)

Chul Won Jung, MD, PhD, Lee-Yung Shih, MD, Zhijian Xiao, MD, Jie Jin, MD, Hsin-An Hou, MD, Xin Du, MD, Ming-Chung Wang, MD, Seonyang Park, MD, PhD, Ki-Seong Eom, MD, PhD, Kenji Oritani, Shinichiro Okamoto, MD, PhD, Tetsuzo Tauchi, MD, Jin Seok Kim, MD, Daobin Zhou, MD, Andres Sirulnik, MD, PhD, Wanda Ruiz, PhD, Taro Amagasaki, PhD, Kazuo Ito, Koichi Akashi, MD, PhD

Blood (2013) 122 (21): 4086.

https://doi.org/10.1182/blood.V122.21.4086.4086

Published: 2013

Journal Articles

Targeting The Dopamine Receptor Signaling Limits The Self-Renewal Of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Tetsuzo Tauchi, MD, Seiichiro Katagiri, MD, Seiichi Okabe, M.D., Yosuke Minami, MD, PhD, Tomoki Naoe, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 1298.

https://doi.org/10.1182/blood.V122.21.1298.1298

Published: 2013

Journal Articles

Combining ABL1 Kinase Inhibitor, Ponatinib and the Histone Deacetylase (HDAC) Inhibitor Vorinostat: A Potential Treatment for BCR-ABL Positive Leukemia Cells

Seiichi Okabe, M.D., Tetsuzo Tauchi, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2011) 118 (21): 1403.

https://doi.org/10.1182/blood.V118.21.1403.1403

Published: 2011

NARROW

Nilotinib Vs. Dasatinib in Achieving MR 4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212

Interleukin 1 Beta As a Promising Therapeutic Target in ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Targeting Insulin-like Growth Factor in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant Cells

Aurora A Kinase As a Promising Therapeutic Target in Philadelphia Chromosome Positive Leukemia Cells

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

ABL001 with Catalytic-Site Inhibitors Limit the CML Immature Cell Population: Re-Differentiation of CML-iPSCs Study

Peroxisome Proliferator-Activated Receptors: Targets for the Treatment of Philadelphia Chromosome-Positive Leukemia Cells

Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC)

Anti-Leukemic Effects of Venetoclax on Philadelphia Chromosome Positive Leukemia Cells

Anti-Leukemic Activity of Phosphoinositide 3-Kinase Inhibitor, Copanlisib in ABL Tyrosine Kinase Resistant Leukemia Cells

Antitumor Activity of Phosphoinositide 3-Kinases Inhibitor, Copanlisib in Multiple Myeloma Cells

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Efficacy Of The Polo-Like Kinase Inhibitor, Rigosertib Alone Or In Combination With ABL Tyrosine Kinase Inhibitor Against BCR-ABL-Positive Leukemia Cells

High Frequencies Of Switching To 2 nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants

Therapeutic Potential Of Targeting Sphingosine-1-Phosuphate and Sphingosine Kinases In Multiple Myeloma

Activity Of Omacetaxine Mepesuccinate Against Ponatinib Resistant Philadelphia Chromosome Positive Leukemia Cells

A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF)

Targeting The Dopamine Receptor Signaling Limits The Self-Renewal Of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Combining ABL1 Kinase Inhibitor, Ponatinib and the Histone Deacetylase (HDAC) Inhibitor Vorinostat: A Potential Treatment for BCR-ABL Positive Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only